Description

High-purity Lanatoside C, a cardiac glycoside with newly discovered properties in cancer immunotherapy and ferroptosis induction for non-small cell lung cancer (NSCLC) research.

Technical Specifications

• Molecular Formula: C₄₉H₇₆O₂₀
• Molecular Weight: 985.10 g/mol
• Purity: ≥98% (HPLC)
• Appearance: White to off-white crystalline powder
• Solubility: Soluble in DMSO, and methanol; limited water solubility

IUPAC Name: [(2R,3R,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl] acetate

InChI: InChI=1S/C49H76O20/c1-21-43(67-38-17-32(53)44(22(2)62-38)68-39-18-33(64-24(4)51)45(23(3)63-39)69-46-42(58)41(57)40(56)34(19-50)66-46)31(52)16-37(61-21)65-27-9-11-47(5)26(14-27)7-8-29-30(47)15-35(54)48(6)28(10-12-49(29,48)59)25-13-36(55)60-20-25/h13,21-23,26-35,37-46,50,52-54,56-59H,7-12,14-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29-,30+,31+,32+,33+,34-,35-,37+,38+,39+,40-,41+,42-,43-,44-,45-,46+,47+,48+,49+/m1/s1

InChIKey: JAYAGJDXJIDEKI-PTGWOZRBSA-N

Canonical SMILES: CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CC(C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)O)OC7CC(C(C(O7)C)OC8CC(C(C(O8)C)OC9C(C(C(C(O9)CO)O)O)O)OC(=O)C)O

Isomeric SMILES: C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)OC(=O)C)O

Synonyms: lanatoside C; 17575-22-3; Isolanid; Cedilanid; Celadigal; Cetosanol; Isolanide; Lanimerck; …

Botanical Source:

Key Research Findings (2024-2025)

1. Cancer Immunotherapy

   • Inhibits FOXP3 transcriptional activity
   • Activates E3 ligase STUB1
   • Promotes antitumor immunity
   • Synergizes with PD-1 inhibitors

2. NSCLC Research

   • Induces ferroptosis
   • Regulates SLC7A11/GPX4 signaling
   • Enhances tumor sensitivity
   • Reduces tumor size and weight

Research Applications

1. Cancer Research

   • Regulatory T cell studies
   • FOXP3/RUNX1 complex inhibition
   • Drug resistance investigations
   • Combination therapy studies

2. Cell Death Mechanisms

   • Ferroptosis pathways
   • Cell viability analysis
   • LDH release studies
   • Mitochondrial function

Mechanism of Action

• Activates STUB1 E3 ligase
• Causes RUNX1 degradation
• Inhibits FOXP3 activity
• Modulates SLC7A11/GPX4 pathway

Storage & Handling

• Store at -20°C
• Protect from light
• Avoid repeated freeze-thaw cycles
• Stock solution guidelines provided
• Working concentration: 0.4 µM recommended

Quality Assurance

• GMP-compliant manufacturing
• Rigorous quality control
• Complete analytical documentation
• Traceable lot numbers
• Stability monitoring program

Key Research Areas

1. Immunotherapy

   • Treg inhibition
   • Antitumor immunity
   • PD-1 inhibitor synergy
   • FOXP3 regulation

2. Lung Cancer Research

   • Ferroptosis induction
   • Tumor growth inhibition
   • Cell death mechanisms
   • Biomarker studies

This premium-grade Lanatoside C is designed for research institutions and pharmaceutical companies advancing cancer therapeutic development and scientific research.

For research and development purposes only. Not for human consumption or clinical use.